Sign inJoin waitlistJoin the waitlist

Jaclyn Wall

Physician · Virginia Commonwealth University School of Medicine

Credentials: · · · · · · ·

History

Virginia Commonwealth University School of Medicine
2024–Present

Gynecologic Oncology
University of Alabama Hospital
2019–2022
Obstetrics and Gynecology
Duke University Hospital
2015–2019
Virginia Commonwealth University School of Medicine
2011–2015

Research

The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer
Review · Expert Opinion on Investigational Drugs · 2020 · First of 3 authors · 57 citations
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
Gynecologic Oncology · 2020 · 53 citations
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy
Gynecologic Oncology · 2021 · First of 9 authors · 41 citations

Rebecca Arend
10 papers · 5 as a resident
Warner Huh
4 papers
Alexi Wright
3 papers
Andrea Enzinger
3 papers
Larissa Meyer
3 papers
ML
Margaret Liang
3 papers
MB
Marie Bakitas
3 papers
McKenzie Foxall
3 papers
Michael Birrer
3 papers
Rachel Pozzar
3 papers
Susana Campos
3 papers
Ursula Matulonis
3 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034